|

FAP immunosuppressive CAR-DC Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Second Affiliated Hospital, School of Medicine, Zhejiang University2

Indications

Other2 trials

Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Phase 1/2
Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.